Search clinical trials for: KRAS Mutant Advanced Non-Small Cell Lung Cancer

Total 163401 results

Revolution Medicines, Inc.

Recruiting

Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC)

United States, Puerto Rico
Revolution Medicines, Inc.

Recruiting

Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States
Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
Revolution Medicines, Inc.

Recruiting

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC) | Colorectal Cancer (CRC)

United States, Italy, Spain, Malaysia, Korea, Republic of, France, Australia, Thailand, Taiwan, Poland, Singapore, Czechia, Serbia
Novartis Pharmaceuticals

Recruiting

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03)

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Colorectal Cancer | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal | Non-Small Cell Lung Carcinoma | KRAS G12C Mutant Solid Tumors

Korea, Republic of, Spain, Belgium, United States, France, Germany, Italy, Singapore
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC

Non-Small Cell Lung Cancer

United States
Novartis Pharmaceuticals

Recruiting

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

Non-Small Cell Lung Cancer

China, United States, Korea, Republic of, Canada, Poland, Taiwan, Spain, Lebanon, Malaysia, Turkey, Italy, India, Norway, Croatia, Thailand, Hong Kong, Brazil, Greece, Colombia, Bulgaria, Jordan, Romania, Serbia, Slovenia, Denmark, Vietnam, Estoni... and more
Deciphera Pharmaceuticals LLC

Recruiting

A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors

Melanoma | Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Pancreatic Ductal Adenocarcinoma

United States
Shanghai Chest Hospital

Completed

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Non Small Cell Lung Cancer

China
Taiho Oncology, Inc.

Terminated

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Non-Small Cell Lung Cancer | KRAS Gene Mutation | Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations

United States
Memorial Sloan Kettering Cancer Center

Completed

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | KRAS Gene Mutation

United States
Abramson Cancer Center at Penn Medicine
Pfizer

Active, not recruiting

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | KRAS Mutation-Related Tumors

United States
National Cancer Institute (NCI)
University of Chicago; City of Hope Medical Center; University of Southern California and other collaborators

Completed

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Non Small Cell Lung Carcinoma

United States
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer

United States
TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics

Recruiting

Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NSCLC | Metastatic Lung Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Metastatic Non-Small Cell Lung Cancer | KRAS G12C

United States, Australia
Memorial Sloan Kettering Cancer Center
Amgen

Recruiting

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Non Small Cell Lung Cancer

China
Ikena Oncology

Recruiting

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Colorectal Cancer | Pancreatic Cancer | Thyroid Carcinoma | Solid Tumor, Adult | Malignant Melanoma | Non-Small Cell Lung Carcinoma | BRAF Gene Mutation | Gliomas, Malignant | Ras (Kras or Nras) Gene Mutation | CRAF Gene Mutation

United States
Yonsei University

Not yet recruiting

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases (ELPIS)

Non Small Cell Lung Cancer

Korea, Republic of
Immuneering Corporation

Recruiting

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Pancreas Adenocarcinoma | Non-small Cell Lung Cancer | Advanced Solid Tumor (Phase 1) | Malignant Melanoma (Cutaneous)

United States
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Non-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

United States
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.

Recruiting

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Advanced Solid Tumor | Non-small Cell Lung Cancers

United States
Affini-T Therapeutics, Inc.

Recruiting

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Colorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Pancreatic Ductal Adenocarcinoma | KRAS G12V

United States
Sun Yat-sen University

Not yet recruiting

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

China
Dizal Pharmaceuticals

Recruiting

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients With EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Non-small Cell Lung Cancer

China
Bridge Biotherapeutics, Inc.

Recruiting

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, Czechia, Italy, Portugal, Hong Kong, Thailand, Singapore, Bulgaria, Turkey, Argentina, Belgium, G... and more
AstraZeneca

Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC in Routine Practices in Russia (PASSAT)

Unresectable /Inoperable Locally Advanced (Stage II-III) Non-small Cells Lung Cancer (NSCLC)

Russian Federation
NYU Langone Health

Recruiting

Ladarixin With Sotorasib in Advanced NSCLC

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation (Krascendo 170)

Non-Small Cell Lung Cancer

Korea, Republic of, Canada, United States, Australia, Brazil, China, United Kingdom, Israel, Belgium, Netherlands, Argentina, Spain, Taiwan, Italy, Poland, Turkey, Sweden, Switzerland
Zhejiang Genfleet Therapeutics Co., Ltd.

Recruiting

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Advance Non-small Cell Lung Cancer

Spain, Italy, Greece
Mirati Therapeutics Inc.

Recruiting

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Pancreatic Adenocarcinoma | Solid Tumor | Advanced Solid Tumor | Non-small Cell Lung Cancer | Colo-rectal Cancer

United States
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C (CODEBREAK-IGR)

Non Small Cell Lung Cancer | KRAS P.G12C

France
ETOP IBCSG Partners Foundation
Janssen Pharmaceuticals

Recruiting

AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI (AMAZE-lung)

Non Small Cell Lung Cancer

Spain, France, Switzerland, United Kingdom, Singapore, Italy, Netherlands
Immuneering Corporation

Recruiting

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Pancreatic Adenocarcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC) | Malignant Melanoma (Cutaneous)

United States
Mirati Therapeutics Inc.

Recruiting

A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Solid Tumor | Non Small Cell Lung Cancer | Advanced Solid Tumor | Colo-rectal Cancer

United States, Puerto Rico
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
Jiesi Yingda Pharmaceutical Technology (Suzhou)...

Recruiting

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer (VIC-1911)

Advanced Non-small Cell Lung Cancer

China
Yonsei University

Not yet recruiting

An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib (breakthrough)

Non Small Cell Lung Cancer

Korea, Republic of
Beijing Chest Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2

HER2 Mutant Non-small Cell Lung Cancer
J Ints Bio

Recruiting

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

EGFR Mutant Advanced Non-small Cell Lung Cancer

Korea, Republic of, United States, Thailand
Revolution Medicines, Inc.

Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States
Verastem, Inc.
Mirati Therapeutics Inc.

Recruiting

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (RAMP204)

Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | Malignant Neoplasm of Lung | Malignant Neoplastic Disease | KRAS Activating Mutation

United States
Navire Pharma Inc., a BridgeBio company
Bristol-Myers Squibb

Recruiting

SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Solid Tumor | Non Small Cell Lung Cancer

United States
Sung Yong Lee
Yuhan Corporation

Recruiting

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

Non-small Cell Lung Cancer Stage III | Non-squamous Non-small-cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
Sun Yat-sen University
GeneCast Biotechnology Co., Ltd.; Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA (FOCUS-C)

Non-small Cell Lung Cancer

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor

Non-Small Cell Lung Cancer | Solid Tumor | Medullary Thyroid Cancer

China

Search clinical trials for: KRAS Mutant Advanced Non-Small Cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations